Short Interest in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Grows By 29.3%

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 290,900 shares, a growth of 29.3% from the March 15th total of 224,900 shares. Based on an average daily trading volume, of 152,900 shares, the days-to-cover ratio is currently 1.9 days. Approximately 1.8% of the shares of the company are short sold.

NeuroSense Therapeutics Stock Performance

Shares of NRSN stock traded up $0.00 during mid-day trading on Friday, reaching $1.03. The company’s stock had a trading volume of 134,261 shares, compared to its average volume of 240,965. The firm’s 50-day moving average is $1.06 and its two-hundred day moving average is $1.11. NeuroSense Therapeutics has a 1-year low of $0.51 and a 1-year high of $1.50. The company has a market cap of $14.12 million, a P/E ratio of -1.61 and a beta of 1.36.

NeuroSense Therapeutics (NASDAQ:NRSN) last released its quarterly earnings data on Monday, April 7th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.06.

Hedge Funds Weigh In On NeuroSense Therapeutics

Several large investors have recently made changes to their positions in NRSN. XTX Topco Ltd lifted its position in NeuroSense Therapeutics by 40.9% during the 3rd quarter. XTX Topco Ltd now owns 45,996 shares of the company’s stock valued at $58,000 after purchasing an additional 13,346 shares during the period. Jane Street Group LLC acquired a new position in NeuroSense Therapeutics in the fourth quarter valued at approximately $78,000. Finally, Citadel Advisors LLC boosted its stake in NeuroSense Therapeutics by 640.9% in the fourth quarter. Citadel Advisors LLC now owns 253,997 shares of the company’s stock valued at $305,000 after acquiring an additional 219,717 shares during the last quarter. Institutional investors and hedge funds own 1.04% of the company’s stock.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.